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Tuberculous meningitis (TBM) is the most lethal form of tuberculosis, and new treatments that improve
outcomes are required. We randomly assigned adults with TBM to treatment with standard antituberculosis
treatment alone or in combination with ciprofloxacin (750 mg/12 h), levofloxacin (500 mg/12 h), or gatifloxacin
(400 mg/24 h) for the first 60 days of therapy. Fluoroquinolone concentrations were measured with plasma and
cerebrospinal fluid (CSF) specimens taken at predetermined, randomly assigned times throughout treatment.
We aimed to describe the pharmacokinetics of each fluoroquinolone during TBM treatment and evaluate the
relationship between drug exposure and clinical response over 270 days of therapy (Controlled Trials number
ISRCTN07062956). Sixty-one patients with TBM were randomly assigned to treatment with no fluoroquinolone
(n  15), ciprofloxacin (n  16), levofloxacin (n  15), or gatifloxacin (n  15). Cerebrospinal fluid penetra-
tion, measured by the ratio of the plasma area under the concentration-time curve from 0 to 24 h (AUC0–24)
to the cerebrospinal fluid AUC0–24, was greater for levofloxacin (median, 0.74; range, 0.58 to 1.03) than for
gatifloxacin (median, 0.48; range, 0.47 to 0.50) or ciprofloxacin (median, 0.26; range, 0.11 to 0.77). Univariable
and multivariable analyses of fluoroquinolone exposure against a range of different treatment responses
revealed worse outcomes among patients with lower and higher plasma and CSF exposures than for patients
with intermediate exposures (a U-shaped exposure-response). TBM patients most likely to benefit from
fluoroquinolone therapy were identified, along with exposure-response relationships associated with improved
outcomes. Fluoroquinolones add antituberculosis activity to the standard treatment regimen, but to improve
outcomes of TBM, they must be started early, before the onset of coma.
Tuberculous meningitis (TBM) causes death or severe dis-
ability in half of those afflicted, yet drug treatment has not
changed since the introduction of rifampin in the 1970s (35).
While early antituberculosis chemotherapy in combination
with adjunctive corticosteroids improves outcomes (33), fur-
ther improvements are urgently required. The in vitro activity
of fluoroquinolones against Mycobacterium tuberculosis has
been recognized for decades (36). While fluoroquinolones are
considered essential for the treatment of multidrug-resistant
tuberculosis (10) and may have a role in the treatment of
drug-sensitive pulmonary tuberculosis (11), their role in the
treatment of TBM is uncertain.
Fluoroquinolones may improve TBM outcomes by enhanc-
ing the initial antimycobacterial activity of the standard anti-
tuberculosis drug regimen. Additionally, they may be useful for
patients unable to take isoniazid or rifampin because of patient
intolerance or bacterial drug resistance to these agents. The
optimal fluoroquinolone agent and exposure for TBM treat-
ment have not been defined. There have been case reports or
small case series describing ciprofloxacin, levofloxacin, and
moxifloxacin pharmacokinetics (PKs) in TBM treatment (1, 2,
4, 7, 13, 38), but there are no clinical data evaluating gatifloxa-
cin or fluoroquinolone exposure-response relationships for this
patient population.
Our aim was to evaluate the pharmacokinetics of fluoro-
quinolones and exposure-response relationships for the effi-
cacy of these agents in patients with TBM in the context of
standard combination antituberculosis chemotherapy. This is
the first study comparing the plasma and cerebrospinal fluid
(CSF) pharmacokinetics of ciprofloxacin, gatifloxacin, and
levofloxacin in patients with TBM and the first to evaluate the
contribution of fluoroquinolone exposure to outcomes in this
severely ill population.
MATERIALS AND METHODS
Setting and study participants. Study participants were recruited from the
Hospital for Tropical Diseases (HTD) in Ho Chi Minh City, Vietnam, a 500-bed
secondary and tertiary referral hospital for infectious diseases. All adults (14
years of age) with suspected TBM were eligible to enter the study. Patients were
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ineligible if they were pregnant, fluoroquinolones were contraindicated for any
reason, or consent was not obtained.
The ethical and scientific committees of the HTD and the Health Service of
Ho Chi Minh City and the Oxford Tropical Research Ethics Committee ap-
proved the study protocol. Written informed consent for study participation was
obtained from all patients or their relatives. The International Standard Ran-
domized Controlled Trial number is ISRCTN07062956.
Treatment. Patients received daily oral treatment with isoniazid (5 mg/kg of
body weight/day; maximum, 300 mg) and rifampin (10 mg/kg/day; maximum, 600
mg) for 9 months. Oral pyrazinamide (30 mg/kg/day; maximum, 2 g/day) and
intramuscular streptomycin (20 mg/kg/day; maximum, 1 g/day) were given for the
first 3 months. Ethambutol (30 mg/kg/day; maximum, 1.2 g/day) was substituted
for streptomycin in HIV-infected adults and was added to the regimen for 3
months for those previously treated for tuberculosis. Adjunctive dexamethasone
was given for the first 6 to 8 weeks, as described previously (33). Drugs were
given by nasogastric tube for those unable to swallow. No HIV-infected patients
received antiretroviral drugs because they were unavailable at the time of the
study.
Patients were allocated by a computer-generated sequence of random num-
bers into blocks of 10 (Microsoft Excel, 1997 to 2003) to receive the above-
described treatments, alone or in combination with open-label oral ciprofloxacin
(750 mg/12 h), levofloxacin (500 mg/12 h), or gatifloxacin (400 mg/24 h), for the
first 60 days.
Laboratory investigations. Paired blood and cerebrospinal fluid (CSF) speci-
mens were taken for the assay of fluoroquinolone concentrations upon admission
and at days 2, 7, 30, 60, and 270 of treatment. Unless clinically contraindicated,
the timing of the lumbar puncture was randomized to 0 to 8, 8 to 16, or 16 to 24 h
following antituberculosis drug administration. Two additional blood specimens
were taken within 24 h of drug administration at predetermined, randomly
assigned times before and after the lumbar puncture. Thus, for each patient, on
each sample collection day, one randomly timed CSF sample and two randomly
timed plasma samples were collected; this procedure was repeated on up to five
occasions per patient.
High-pressure liquid chromatography tandem mass spectrometry (LC/MS/
MS) methods were developed at the Ordway Research Institute and used to
determine ciprofloxacin and gatifloxacin concentrations in plasma and CSF and
levofloxacin concentrations in CSF. Plasma levofloxacin concentrations were
determined by using a high-pressure liquid chromatography mass spectrometry
(LC/MS) method, which was also developed at the Ordway Research Institute.
Samples (0.050 ml) were deproteinated and analyzed by using a Phenomenex
Luna Phenyl-Hexyl column (150 by 4.6 mm, 5 m) with mobile phases of 0.1%
formic acid in water and 0.1% formic acid in acetonitrile interfaced with either
an ABSciex API5000 (LC/MS/MS) or an Agilent LC/MSD (LC/MS) instrument.
All M. tuberculosis isolates were tested for drug susceptibility by using the 1%
proportion method on Lowenstein-Jensen medium. The laboratory performing
this test is accredited by the WHO and is a Western Pacific Region WHO
supranational tuberculosis reference laboratory. The MIC of ofloxacin for each
isolate was determined by the microtiter dilution method. Ofloxacin MIC values
were determined and correlated to the potencies of other quinolones by using
potency relationships documented in the literature. For example, levofloxacin
was more active than ofloxacin, as it is the active component of the racemic
mixture that is ofloxacin. The MIC values for the culture-negative patients
were designated the MIC50 values based on those reported in the literature
(27, 28, 29).
Potential fluoroquinolone resistance was investigated with locked nucleic acid
probe real-time PCR to detect mutations in gyrA (39).
Assessment of clinical outcome. Clinical data were recorded prospectively over
270 days of therapy and entered into an electronic database. Clinical outcomes
assessed after 270 days of treatment included survival, death or disability, and
disease relapse. Time to death, time to fever resolution, and time to coma
clearance were assessed over this period. Coma was assessed by the Glasgow
coma score (GCS), which is based on the best eye, verbal, and motor responses
(31). The lowest possible score (the sum of the 3 responses) is 3 (which indicates
deep coma), while the highest is 15 (fully awake person). Neurological disability
was assessed by using Rankin and “simple-questions” scores as previously de-
scribed (33). Disease relapse was defined as the onset of new focal neurological
signs or a decrease in the GCS of 2 points or more for 2 or more days following
more than 7 days of clinical stability or improvement at any time after random-
ization. Time to fever resolution was defined as the time in days from random-
ization to the observation of a maximum daily body temperature of lower than
37.5°C for more than five consecutive days. Time to coma clearance was defined
as the time in days from randomization to the observation of a GCS of 15 for
more than two consecutive days.
Determination of plasma and CSF fluoroquinolone exposures. A sequential
population pharmacokinetic analysis approach, using nonlinear mixed-effects
methodology as implemented in the NONMEM, version 6, software package (6),
was used to evaluate the sparsely sampled plasma and CSF concentration-time
data for each fluoroquinolone. One- and two-compartment models with first-
order absorption and elimination were evaluated to describe the plasma concen-
tration-time data for each drug (2, 15, 24, 25).
Structural model development. Differential equations and initial conditions
(ICs) describing the amount of drug in the depot (Apo), plasma (Ap), and
nonspecific tissue (AT) compartments are shown in equations 1, 2, and 3, respec-
tively:
dApo
dt
  ka  Apo, IC F  dose (1)
dAp
dt
 ka  Apo
CLd
Vp
 AT CLVc  CLdVc   Ap, IC 0 (2)
dAT
dt

CLd
Vc
 Ap
CLd
Vp
 AT, IC 0 (3)
For the one-compartment models evaluated, each drug was parameterized by
using a first-order absorption rate constant (ka), the apparent central volume of
distribution (Vc/F) and plasma clearance (CL/F), and an absorption lag time
(ALAG). For the two-compartment models evaluated, two additional parame-
ters were included, the distribution clearance (CLd/F) and peripheral volume of
distribution (Vp/F). Apparent PK parameters were calculated due to the absence
of intravenous data, which are required to determine the bioavailability (F) for
each drug.
Individual plasma PK parameter estimates for each drug were utilized with the
equations shown above to generate plasma drug concentrations (Cp Ap/Vc) for
use as a driving function to characterize the concentrations of each drug in the
CSF (CCSF), as shown in Fig. S1 in the supplemental material. An effect-site
compartment model was utilized, which assumed that the total amount of
drug entering the CSF from plasma was negligible for each drug, as shown in
equation 4:
dCCSF
dt
 kapp  Cp krem  CCSF (4)
where kapp and krem represent the first-order rate constants for the transfer of the
drug to and the eventual removal of the drug from the CSF, respectively.
FIG. 1. Flow of participants through the trial.
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The between-patient variability (2) was described for each PK parameter,
where possible, by using an exponential error model, assuming that each PK
parameter is log-normally distributed. For example, the individual gatifloxacin
CL/F equals [population mean gatifloxacin CL/F]  expCL/F, where CL/F is a
Gaussian random error term representing the difference between each of the
individual CL/F values and the population mean CL/F, with the distribution of
CL/F having a mean of zero and a variance of 2. Between-occasion variability
was also estimated when necessary. Residual variability was described by using a
constant coefficient of variation (CV) error model.
Using the individual post hoc parameter estimates obtained for each patient,
steady-state plasma and CSF drug exposures, represented by the area under the
concentration-time curve over a 24-h period (AUC0–24) for each sampling oc-
casion, were calculated for each individual patient who received a fluoroquin-
olone. Steady-state AUC0–24 values for each patient were averaged across sam-
pling occasions. CSF penetration, as measured by the ratio of the mean steady-
state CSF AUC0–24 to the mean steady-state plasma AUC0–24, was then
calculated.
Univariable analyses. We examined the relationships between plasma and
CSF fluoroquinolone exposure and survival, death or disability, and disease
relapse by 270 days of treatment and time to death, time to fever resolution, and
time to coma clearance. Analyses for time to coma clearance were limited to
those patients with a GCS of 14 or lower at the start of treatment. Plasma and
TABLE 1. Baseline characteristics of all patients recruited for the study
Variable
Value for group receiving:
Ciprofloxacin
(n  16)
Gatifloxacin
(n  15)
Levofloxacin
(n  15)
No fluoroquinolone
(n  15)
Median age (yr) (min, max) 39 (17, 75) 24 (16, 70) 33 (18, 68) 36 (15, 82)
No. of male patients (%) 10 (62.5) 5 (33.3) 9 (60.0) 12 (80.0)
No. of patients with previous tuberculosis treatment (%) 0 0 2 (13.3) 0
No. of patients with HIV infection (%) 0 (14 tested) 0 (15 tested) 2 (14.3) (14 tested) 1 (13 tested)
Median wt (kg) (min, max) 50 (21, 65) 48 (34, 58) 48 (31, 60) 49 (40, 68)
Median duration of symptoms before treatment (days) (min, max) 14 (6, 60) 16 (6, 40) 16 (4, 33) 13 (6, 36)
Mean GCS (range) 14 (6-15) 13 (3-15) 13 (4-15) 13 (7-15)
No. of patients with cranial nerve palsy present (%) 6 (37.5) 7 (46.7) 5 (33.3) 6 (40.0)
No. of patients with hemiplegia present (%) 2 (12.5) 2 (13.3) 2 (13.3) 1 (6.7)
No. of patients with MRC disease severity gradea (%) of:
I 4 (25.0) 2 (13.3) 3 (20.0) 3 (20.0)
II 9 (56.3) 9 (60.0) 8 (53.3) 9 (60.0)
III 3 (18.8) 4 (26.7) 4 (26.7) 3 (20.0)
Median serum creatinine concn (mg/dl) (min, max) 75 (57, 138) 77 (45, 105) 64 (41, 97) 70 (52, 170)
Median plasma sodium concn (mmol/liter) (min, max) 130 (123, 143) 130 (119, 145) 131 (151, 138) 137 (122, 144)
Median CSF opening pressure (cm H2O) (min, max) 18 (2, 50) 33 (11, 42) 24 (8, 40) 21 (15, 44)
Median CSF total white cell count (103 cells/ml) (min, max) 243 (60, 955) 295 (64, 1,566) 335 (1, 985) 325 (50, 2,200)
Median % of CSF neutrophils (min, max) 39 (2, 91) 14 (1, 75) 22 (2, 74) 50 (4, 90)
Median % of CSF lymphocytes (min, max) 62 (9, 96) 86 (25, 99) 79 (26, 98) 50 (10, 96)
Median CSF total red cell count (103 cells/ml) (min, max) 97 (0, 7,200) 37 (0, 80) 60 (0, 2,200) 15 (0, 10,650)
Median CSF total protein concn (mg/dl) (min, max) 145 (27, 312) 91 (40, 368) 105 (24, 606) 99 (38, 485)
Median CSF lactate concn (mmol/liter) (min, max) 4.4 (2.7, 9.2) 6.1 (4.1, 8.9) 4.5 (3.4, 8.2) 5.8 (3.3, 10.7)
Median ratio of CSF/blood glucose (min, max) 0.23 (0.06, 0.38) 0.19 (0.06, 0.38) 0.23 (0.09, 0.41) 0.21 (0.02, 0.62)
No. of patients with acid-fast bacilli seen or cultured from the
CSF (%)
11 (68.8) 10 (66.7) 8 (53.3) 10 (66.7)
No. of patients with susceptibility testing result of:
Fully susceptible 7 5 3 3
Isoniazid resistant 0 1 0 2
Streptomycin resistant 0 2 0 0
Isoniazid and streptomycin resistant 0 0 0 1
a According to guidelines from the British Medical Research Council (MRC). Grade I, alert and orientated with no focal neurological signs; grade II, disorientated
(GCS of 11 to 14) and/or focal neurological signs; grade III, comatose (GCS of 11) with or without focal neurological signs (9).
TABLE 2. Summary statistics for selected plasma and CSF fluoroquinolone exposure measures
Drug and dose
Mean AUC0-24 (mg  h/liter) (min, max)a Mean CSF AUC0-24/plasma
AUC
0-24
ratio (min, max)cPlasma Free-drug plasmab CSF
Ciprofloxacin
500 mg twice daily (n  2) 22.5 (14.6, 30.4) 15.7 (10.2, 21.3) 6.97 (4.45, 9.49) 0.31 (0.31, 0.31)
750 mg twice daily (n  13) 31.2 (13.2, 50.0) 21.8 (9.24, 35.0) 6.95d (2.30, 14.9) 0.26d (0.11, 0.77)
Gatifloxacin at 400 mg once daily (n  14) 41.2 (34.2, 85.7) 32.9 (27.4, 68.5) 20.0 (16.5, 41.5) 0.48 (0.47, 0.50)
Levofloxacin at 500 mg twice daily (n  14) 155 (81.1, 284) 107 (56.0, 196) 94.1 (53.1, 208) 0.74 (0.58, 1.03)
a Represents the mean exposure estimates across all occasions for each patient.
b Steady-state plasma AUC0-24 values for fluoroquinolones were corrected for protein binding based on point estimates for percentages of drug bound to serum
proteins of 30%, 20%, and 31% for ciprofloxacin, gatifloxacin, and levofloxacin, respectively.
c The ratio of the mean steady-state CSF AUC0-24 to the mean steady-state plasma AUC0-24, also referred to as the penetration ratio.
d Based on data for 12 patents.
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CSF fluoroquinolone exposure data were each pooled for analysis, and plasma
AUC0–24 values were corrected for protein binding (5, 8, 23) and normalized by
the MIC for M. tuberculosis to derive plasma and CSF AUC0–24/MIC ratios,
respectively. Univariable analyses were conducted to evaluate both plasma and
CSF AUC0–24/MIC ratios as independent exposure variables. Relationships for
dichotomous outcomes were examined by using chi-square or Fisher’s exact tests
for categorical independent variables and logistic regression for continuous in-
dependent variables. Relationships for time-to-event outcomes were examined
by using log rank tests for categorical variables and Cox regression for continu-
ous variables. Univariable relationships for each outcome were also evaluated for
patient age, GCS, creatinine clearance rate, plasma sodium concentration, ratio
of CSF/blood glucose, and CSF total protein concentration, lactate concentra-
tion, total white cell count, and neutrophil percentage.
Each independent variable was evaluated in its original form and as two- and
three-group categorical variables relative to each outcome to account for poten-
tial nonlinearity and nonmonotonicity, respectively. Two-group independent
variables were constructed by using the resulting split of a classification tree for
a given dichotomous outcome and by using a cutoff maximizing the hazard ratio
estimate from a univariable Cox regression model for a given time-to-event
outcome. Three-group independent variables were constructed by determining a
pair of cutoff values that minimized the likelihood ratio P value using either
logistic regression for a dichotomous outcome or Cox regression for a time-to-
event outcome.
Multivariable analyses. Multivariable analyses were conducted for each out-
come by first constructing a base covariate model using the forward inclusion of
independent variables with an entry criterion of a P value of 0.05. Logistic
regression was used to evaluate relationships between independent variables and
dichotomous outcomes, and Cox regression was used for time-to-event out-
comes. Likelihood ratio P values were assessed throughout the forward inclusion
process. All non-exposure-independent variables (including the continuous and
two- and three-group forms of each variable) were considered for inclusion into
the base model. However, once a single form of a given independent variable
entered the model, no other forms of the same variable were considered for entry
at subsequent steps. The limits placed on the number of independent variables
included in a model were based on recommendations by Hosmer and Lemeshow
for logistic regression (18). For the time-to-event outcomes, these criteria were
similarly followed (since only censored patients limit the available information).
Once base models were constructed, exposure-response relationships for each
exposure variable were then considered. The resulting covariate-adjusted rela-
tionships were assessed to understand the differences relative to those observed
with the univariable analyses.
RESULTS
Sixty-one adults with suspected TBM were recruited to the
study between April 2003 and January 2005. A TBM diagnosis
was confirmed by a positive CSF smear for acid-fast bacilli
(31/61 [50.8%]) or mycobacterial culture from 39/61 (63.9%)
patients. Fifteen patients were treated with standard antituber-
culosis drugs alone, and 16 received ciprofloxacin, 15 received
levofloxacin, and 15 received gatifloxacin (Fig. 1). Three pa-
tients, each receiving one of the fluoroquinolones, died and
thus did not contribute any plasma or CSF data. Two patients,
both given levofloxacin, were lost to follow-up after 28 and 100
days of treatment, respectively; these patients were included in
the time-to-event analyses but excluded from the analyses of
dichotomous outcomes. Baseline clinical variables were similar
FIG. 2. Comparison of CSF penetrations among the fluoroquino-
lones evaluated. Box plots of the ratio of the mean steady-state CSF
AUC0–24 to the mean steady-state plasma AUC0–24 are shown for each
agent. Observed data are represented by open circles.
TABLE 3. Summary of P values and directional assessments for univariable relationships between outcome and independent variables
Independent variablea
P value for outcome
Survival Death/disabilityc Relapsed Time todeath
Time to
fever resolutione
Time to
coma clearancef
Plasma fluoroquinolone AUC0-24/MIC ratio 0.031 
b 0.008 U 0.12b 0.014 b 0.039 U 0.063 Ub
CSF fluoroquinolone AUC0-24/MIC ratio 0.004  0.016 U 0.10 0.003 
b 0.193 0.454
Age (yr) 0.003(2) \ 0.049(2) / 0.041(3) / 0.023(2) \ 0.058(2) \ 0.353(3)
GCS 0.002(2) / 0.001(2) \ 0.015(3)  0.001(2) / 0.189(3) 0.001(3) \
Creatinine clearance (mg/dl) 0.11(2) 0.033(3) U 0.05(3)  0.17(3) 0.013(2) \ 0.001(3) U
Plasma sodium concn (mmol/liter) 0.10(3)  0.036(3)  0.13(3) 0.105(3) 0.193(3) 0.053(3) 
CSF/blood glucose ratio 0.16(2) 0.21(3) 0.035(2) \ 0.054(3)  0.063(3)  0.66(2)
CSF total protein concn (mg/dl) 0.08(3)  0.14(3) 0.12(3) 0.105(2) 0.28(1) 0.299(2)
CSF lactate concn (mmol/liter) 0.032(3) \ 0.036(3)  0.008(3) U 0.027(1) \ 0.073(3)  0.053(3) U
CSF total white cell count (103 cells/ml) 0.006(3)  0.001(3)  0.008(3)  0.006(3)  0.019(3)  0.489(2)
CSF neutrophils (%) 0.028(3)  0.17(3) 0.010(3) U 0.049(3)  0.043(2) \ 0.113(2)
a For independent-exposure variables, the reported P values and directionalities are those of the three-group variable. Directionality is reported only for P values
of 0.10. For three-group exposure variables with P values of 0.10, only one case was identified for which the P value was 0.10 for another form of exposure. A
P value of 0.09 was reported for the relationship between plasma AUC0-24/MIC ratio and relapse. For non-exposure-independent variables, the P value reported is the
lowest among the continuous (1), two-group (2), and three-group (3) variables, with the corresponding observed directionality. Directionality is indicated as follows:
, the outcome likelihood or time to event tends to be highest for a middle group; U, the outcome likelihood or time to event tends to be lowest for a middle group;
/, the outcome likelihood or time to event tends to be highest for higher values of the independent variable; \, the outcome likelihood or time to event tends to be lowest
for higher values of the independent variable.
b Cases for which the two-group independent exposure variable produced a smaller P value than the P value reported for the three-group form of that particular
exposure variable.
c Neurological disability was assessed for survivors after 270 days of treatment using the Rankin and “simple-questions” disability scores as previously described (33).
d Relapse of disease was defined as the onset of new focal neurological signs or a decrease in the GCS of 2 points or more for 2 or more days following more than
7 days of clinical stability or improvement at any time after randomization.
e Time to fever resolution was defined as the time in days from randomization to the observation of a maximum daily body temperature of lower than 37.5°C for more
than five consecutive days.
f Time to coma clearance was defined as the time in days from randomization to the observation of a GCS of 15 for more than two consecutive days.
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among the 4 treatment groups (Table 1). Isolates resistant to
isoniazid and/or streptomycin were recovered from 6 patients
(25% of those tested). None of the isolates were resistant to
rifampin or ofloxacin.
Assay performance. Plasma assays were linear over a con-
centration range from 0.050 to 10.0 g/ml (r2  0.984) for each
of the fluoroquinolones. The interday precision (percent CV
[%CV]) and accuracy (percent recovery) ranged from 2.19 to
8.01% and 88.7 to 96.0% for ciprofloxacin, 2.30 to 7.08% and
92.0 to 97.7% for gatifloxacin, and 5.20 to 8.21% and 91.0 to
101% for levofloxacin, respectively. CSF assays were linear
over concentration ranges from 0.005 to 1.0 g/ml (r2  0.982)
for ciprofloxacin and gatifloxacin and from 0.0100 to 5.00
g/ml (r2  0.992) for levofloxacin. The interday precision
(%CV) and accuracy (percent recovery) ranged from 2.54 to
8.54% and 90.0 to 113% for ciprofloxacin, 1.91 to 3.55% and
98.3 to 101% for gatifloxacin, and 3.52 to 7.08% and 96.4 to
108% for levofloxacin, respectively.
Evaluation of plasma and CSF fluoroquinolone exposures.
As demonstrated by the agreement between population mean
predicted steady-state plasma or CSF concentration-time pro-
files and observed plasma or CSF concentration data shown in
Fig. S1 in the supplemental material, the dispositions of gati-
floxacin and levofloxacin in plasma and CSF were each best
described by a one-compartment model with first-order ab-
sorption and elimination along with an effect-site compartment
model. For ciprofloxacin, a two-compartment model with first-
order absorption and elimination along with an effect-site com-
partment model best described plasma and CSF concentra-
tion-time data. A summary of the mean parameter estimates
and standard errors based on the final population pharmaco-
kinetic model for each fluoroquinolone is presented in Table
S1 in the supplemental material. Summary statistics for se-
lected plasma and CSF fluoroquinolone exposure measures
are provided in Table 2. As shown in Fig. 2, CSF penetration,
measured by the ratio of the mean steady-state CSF AUC0-24
to the mean steady-state plasma AUC0-24, was higher for levo-
floxacin (median, 0.74; range, 0.58 to 1.03) than for gatifloxacin
(median, 0.48; range, 0.47 to 0.50) or ciprofloxacin (median,
0.26; range, 0.11 to 0.77) (P  0.001 by a Kruskal-Wallis test).
Moreover, penetration ratios for levofloxacin and ciprofloxacin
were far more variable than those for gatifloxacin.
Relationship between exposure and outcome. (i) Univari-
able analyses. A summary of the P values and directional
assessments for univariable relationships between outcome
and independent variables is shown in Table 3. Univariable
relationships between dichotomous and time-to-event out-
comes and the three-group fluoroquinolone exposure variables
constructed based on these outcomes are shown graphically in
Fig. 3. Consistent and statistically significant “U-shaped” rela-
FIG. 3. Univariable relationships between dichotomous and time-to-event outcomes and three-group drug exposure variables.
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tionships (i.e., apparent nonmonotonic relationship resembling
a U or inverted U) were observed between plasma and CSF
fluoroquinolone exposures and the following outcomes: survival,
death or disability, and time to death. For dichotomous outcomes,
higher percentages of less favorable events were observed for
patients with both low and high fluoroquinolone exposures than
for those with intermediate exposures. For time-to-event out-
comes, patients with intermediate exposures had a longer time to
death and, with the exception of the relationship based on CSF
exposure, a shorter time to fever resolution. Similar U-shaped
exposure-response relationships were observed for the remaining
outcomes, but statistical significance was not consistently ob-
served for both exposure variables.
The GCS was the baseline independent variable most
strongly and consistently associated with poor outcomes
among independent nonexposure variables. Low GCS scores
were significantly associated with death (P  0.002) and death
or disability (P 0.001) and with longer time to death and time
to coma clearance (P  0.001).
(ii) Multivariable analyses. A summary of the P values and
directional assessments for relationships between outcome and
independent variables included in multivariable base models
and individually added three-group exposure variables is
shown in Table 4. Multivariable models are not shown for
relapse, as there were insufficient numbers of events for as-
sessment. Of the independent variables included in each of the
base models, the GCS was most common and, when retained,
demonstrated the strongest association with outcome. As
shown by the P values and directionality for each exposure
variable considered individually for addition to base models,
previously observed univariable relationships for three-group
exposure variables appeared to be minimally affected by cova-
riate adjustments. The similarity between univariable and mul-
tivariable results is most notable for the survival, death-or-
FIG. 3—Continued.
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disability, and time-to-death outcomes, for which U-shaped
exposure-response relationships were almost always preserved.
The distribution of baseline independent variables was eval-
uated across the levels of the three-group exposure variables
for plasma and CSF AUC0-24/MIC ratios to probe for the basis
for the observed U-shaped exposure-response relationships.
Although not always statistically significant (likely a function of
the limited sample size), certain differences among those pa-
tients with low, intermediate, and high fluoroquinolone expo-
sures were evident. As shown in Table 5, patients with high
plasma or CSF exposures were older, had reduced creatinine
clearance rates, lower GCSs, higher concentrations of CSF
total protein and lactate, and/or lower numbers of CSF white
cells and neutrophils than did patients with intermediate ex-
posures. Patients with low exposures were older than those
with intermediate exposures but had similar clinical markers of
disease severity.
DISCUSSION
The goal of this study was to evaluate the pharmacokinetics
of fluoroquinolones and exposure-response relationships for
the efficacy of these agents in patients with TBM in the context
of standard antituberculosis chemotherapy. As a first step,
population pharmacokinetic models describing the disposition
of each fluoroquinolone in plasma and CSF were developed.
These models were similar to those previously described (24),
with the exception of ciprofloxacin, for which the mean popu-
lation estimates of clearance and volume of distribution were
approximately twice those of a previous report (15). Given that
the mean population estimate of the terminal half-life was
similar to that of the previous report (15), reduced bioavail-
ability in our patient population may be the likely explanation
for this discordance. Ciprofloxacin, unlike gatifloxacin and
levofloxacin, is metabolized. Enzyme induction due to coad-
ministration with rifampin may have been a potential factor in
this population (3).
CSF penetration was greater for levofloxacin than for gati-
floxacin or ciprofloxacin at the doses explored. However, pen-
etration ratios for levofloxacin and ciprofloxacin penetration
were highly variable relative to those with gatifloxacin. Since
these drugs have similar molecular weights and protein binding
(5, 8, 23), CSF penetration differences were likely governed by
hydrophobicity/partitioning and the balance between the affin-
ities for influx and efflux active transporters. The higher CSF
penetration for levofloxacin was likely related to the unique
organic anion transporting polypeptide 1A2-mediated uptake
into the brain (20) and an ATP-binding cassette transporter at
the blood-CSF barrier (12), which mediates fluoroquinolone
efflux out of the CSF (21, 22). Overlapping substrate specific-
ities between the influx and efflux transporters make the vec-
torial transport of organic anions highly efficient and may best
explain differences in CSF penetrations among the three
agents. Interestingly, a recent analysis of 4 moxifloxacin-
treated adult TBM patients suggested similar CSF penetra-
tions for moxifloxacin and levofloxacin (2). Gatifloxacin’s more
reliable CSF penetration may be related to the change of its
octanol-water partition coefficient as a function of ambient pH
(26). When one considers the more predictable CSF penetra-
tion and greater in vitro M. tuberculosis activity of gatifloxacin
than those of levofloxacin (28), drug exposure, as measured by
TABLE 4. Summary of P values and directional assessments for relationships between outcome and independent variables included in
multivariable base models and individually added three-group exposure variables
Variablea
P value for outcome
Survival Death/disabilityd Time to death Time tofever resolutionf
Time to
coma clearanceg
Independent
Plasma fluoroquinolone AUC0-24/MIC ratio 0.027 
c 0.028 U 0.06c 0.052 U 0.78e
CSF fluoroquinolone AUC0-24/MIC ratio 0.006  0.026 U 0.033
c 0.22c 0.95
Base model independentb
GCS 0.001(2) / 0.001(2) \ 0.001(1)/ 0.001(1) \
CSF total protein concn (mg/dl) 0.002(2) /
e
CSF neutrophils (%) 0.003(3) 
Creatinine clearance (mg/dl) 0.001(3) 
e
CSF lactate concn (mmol/liter) 0.001(3) 
CSF/blood glucose ratio 0.002(3)  0.027(3) U
e
a For independent-exposure variables, the reported P values and directionalities are those of the three-group variable when added to the base model. Directionality
is reported only for P values of 0.10.
b For the independent variables retained in the base model, the P value reported is either for the continuous (1), two-group (2), or three-group (3) variable, with
the corresponding observed directionality. Directionality is reported for P values of 0.10. Directionality is indicated as follows: , the outcome likelihood or time to
event tends to be highest for a middle group; U, the outcome likelihood or time to event tends to be lowest for a middle group; /, the outcome likelihood or time to
event tends to be highest for higher values of the independent variable; \, the outcome likelihood or time to event tends to be lowest for higher values of the independent
variable. As per the Hosmer and Lemeshow guidelines for dichotomous outcomes (18), base multivariable models for survival and death/disability were limited to
include 1 and 2 independent variables, respectively. Base multivariable models for time to death, time to fever resolution, and time to coma clearance were similarly
limited to 2, 5, and 3 independent variables, respectively. However, as shown by the base models for these outcomes containing 2, 3, and 2 independent variables,
respectively, stepwise modeling procedures stopped before these limits were reached.
c Cases for which the two-group form of an exposure variable produced a smaller P value than the P value reported for the three-group form of that variable.
d Neurological disability was assessed for survivors after 270 days of treatment using the Rankin and “simple-questions” disability scores as previously described (33).
e Notable change in significance (at a P value of 0.10) or direction from the univariable P value reported in Table 3.
f Time to fever resolution was defined as the time in days from randomization to the observation of a maximum daily body temperature of lower than 37.5°C for more
than five consecutive days.
g Time to coma clearance was defined as the time in days from randomization to the observation of a GCS of 15 for more than two consecutive days.
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the CSF AUC0–24/MIC ratio, is higher and less variable for
gatifloxacin, which may translate into improved patient out-
comes. Given the lower ciprofloxacin CSF exposure, the lower
aforementioned bioavailability in this patient population, the
lower in vitro activity against M. tuberculosis than that of gati-
floxacin and levofloxacin (14, 16, 27, 28, 29, 30), and evidence
of resistance emergence upon therapy (17), ciprofloxacin
should not be the preferred fluoroquinolone for the treatment
of TBM.
Using plasma and CSF exposures from the above-described
population pharmacokinetic models, subsequent univariable
analyses of clinical outcomes revealed intriguing results: con-
sistent U-shaped exposure-response relationships were ob-
served for dichotomous and time-to-event outcomes. For ex-
ample, significantly higher proportions of death and death or
disability were observed for patients with lower or higher
plasma and CSF fluoroquinolone exposures than for patients
with intermediate exposures. Also, patients with the lowest and
highest plasma and CSF fluoroquinolone exposures were sig-
nificantly more likely to die more rapidly than those with in-
termediate exposures.
The paradoxical relationship between high CSF exposures
and poor outcomes may be explained by a colinear association
with increased disease severity. As identified here and previ-
ously (19, 33, 34), the baseline GCS was the strongest inde-
pendent predictor of a poor TBM outcome. In addition, re-
duced numbers of CSF white cells and increased lactate CSF
concentrations have also been strongly linked to poor out-
comes (32, 33). In the analyses described here, we found that
those patients with the highest CSF fluoroquinolone exposures
had lower GCSs, the lowest numbers of CSF white cells, and
the highest CSF lactate concentrations.
We hypothesize that the integrity of the blood-brain barrier
is associated with disease severity. Drug penetrates into the
CSF more readily in those with the most severe disease, but the
additional bactericidal activity is insufficient to prevent death
and/or disability. Increased CSF drug penetration in those
patients with severe TBM may also have been enhanced by
higher plasma fluoroquinolone exposures. As with CSF expo-
sure, significant U-shaped relationships between plasma fluo-
roquinolone exposures and poor outcomes were observed. Pa-
tients with the highest plasma exposures were older and had
lower creatinine clearance rates than did those with low or
intermediate exposures. Since the fluoroquinolones studied
are excreted predominantly by the kidneys, impaired renal
function results in increased plasma exposures (37).
As evidenced by the results of multivariable analyses, the
significance of univariable U-shaped exposure-response rela-
tionships was consistently preserved when evaluated in the
presence of other significant independent variables. This was
evident even in the presence of the GCS, which was most
strongly and consistently associated with poor outcomes. Such
findings provide the opportunity to identify TBM patients at
the most risk and most likely to benefit from intervention
including fluoroquinolone therapy.
In summary, these findings have three important implica-
tions. First, TBM patients most likely to benefit from fluoro-
quinolone therapy were identified. Second, fluoroquinolone
exposure-response relationships associated with improved out-
comes were characterized, thus providing a paradigm for fluo-
roquinolone clinical development, including dose regimen se-
lection, for the treatment of TBM patients. Third, the
importance of diagnosing and treating TBM early, before the
onset of coma, is highlighted.
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